Hyperuricemia Agents (antimitotic)

The phrase "Hyperuricemia Agents (antimitotic)" is a compendial or database classification—principally represented by colchicine—rather than a distinct pharmacological class established by the FDA

The phrase "Hyperuricemia Agents (antimitotic)" is a compendial or database classification—principally represented by colchicine—rather than a distinct pharmacological class established by the FDA Although grouped under hyperuricemia therapies, these medications do not lower serum uric acid levels; instead, they serve an anti-inflammatory role primarily indicated for the treatment and prophylaxis of acute gout flares and the management of familial Mediterranean fever

Agents in this grouping exert their therapeutic effects by binding to tubulin and inhibiting microtubule polymerization, which arrests cell division and suppresses neutrophil chemotaxis, degranulation, and inflammasome activation

Agents in this grouping exert their therapeutic effects by binding to tubulin and inhibiting microtubule polymerization, which arrests cell division and suppresses neutrophil chemotaxis, degranulation, and inflammasome activation Although grouped under hyperuricemia therapies, these medications do not lower serum uric acid levels; instead, they serve an anti-inflammatory role primarily indicated for the treatment and prophylaxis of acute gout flares and the management of familial Mediterranean f...

Although grouped under hyperuricemia therapies, these medications do not lower serum uric acid levels; instead, they serve an anti-inflammatory role primarily indicated for the treatment and prophylaxis of acute gout flares and the management of familial Mediterranean fever